<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3892B18D-3348-482D-A854-68726A9D52EE"><gtr:id>3892B18D-3348-482D-A854-68726A9D52EE</gtr:id><gtr:name>Seaside Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3892B18D-3348-482D-A854-68726A9D52EE"><gtr:id>3892B18D-3348-482D-A854-68726A9D52EE</gtr:id><gtr:name>Seaside Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FACE1CD8-52F5-4C87-A20E-2BC5E9739A86"><gtr:id>FACE1CD8-52F5-4C87-A20E-2BC5E9739A86</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Wyllie</gtr:surname><gtr:orcidId>0000-0002-4957-6049</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0E38A76-22A8-4A96-B359-A22677D36A40"><gtr:id>A0E38A76-22A8-4A96-B359-A22677D36A40</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Conell</gtr:otherNames><gtr:surname>Kind</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700967"><gtr:id>CCE54608-13CB-4DE2-B21C-AAC6BA59B949</gtr:id><gtr:title>The cellular basis of FMRP function</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700967</gtr:grantReference><gtr:abstractText>Fragile X syndrome is the most common form of mental retardation that can be inherited from ones? parents. It is caused by the absence of a single protein called the fragile X mental retardation protein or FMRP. As the same implies, the gene that makes FMRP is located on the X chromosome. Men have one copy of the X chromosome whereas women have two copies, each containing a copy of the FMRP gene. Interestingly, the two X-chromosomes in females do not express their genes equally; during early foetal development each cell makes a decision to inactivate one X-chromosome (in a process known as X-inactivation) apparently at random. In the case of females with FXS, if a cell inactivates the chromosome containing the normal gene, the cell will not make FMRP. Similarly, if the cell inactivates the X-chromosome containing the mutant FMR1 gene, the cell will make normal levels of FMRP. Because X-inactivation is random, the severity of neurological defects in females varies depending on the relative number of mutant and normal cells. In mice, we can exploit the fact that females have normal and abnormal cells to learn about how FMRP regulates brain development and whether or not the disease is treatable to certain types of drug treatments. For example the presence of cells with normal levels of FMRP may secrete some factors that rescue the cells that do not express FMRP. Women would only show symptoms if the proportion of normal cells is too low to effectively rescue the mutant cells. In this case identification of the factors by which rescue occurs would provide excellent prospective drug therapies for male and female FXS sufferers. Alternatively, the presence of normal cells may not be able to rescue the mutant cells because the mutant cells do not have the ability to respond to factors made by the normal cells. In this case, alternative forms of treatments that either directly alter the genetics of the mutant cells or that can bypass the normal role of FMRP would have to be pursued. All of the experiments will focus on neurons of the cerebral cortex and hippocampus, brain regions that mediate cognition and memory in mammals. These experiments will therefore guide future research into treatments of FXS. Furthermore, they will be the first experiments to directly examine the development of FXS in females.</gtr:abstractText><gtr:technicalSummary>Fragile X syndrome (FXS) is the most common genetically inherited form of mental retardation. FXS results from the silencing of the fragile X mental retardation 1 gene (FMR1) and loss of the protein it encodes, FMRP. Humans and mice lacking FMRP show abnormalities in dendritic branching, spine density and morphology, and synaptic plasticity. Preliminary evidence from our laboratory has also revealed a defect in the differentiation of the primary somatosensory cortex of mice lacking FMRP. These developmental morphological and physiological changes are likely to underlie the cognitive deficits associated with FXS. 

As its name implies, FXS is an X chromosome-linked disorder. Although females have two X-chromosomes, the process of X-chromosome inactivation results in one of these being silenced. The result is that females heterozygous for the mutant FMR1 allele are mosaics, with some cells expressing normal levels of FMRP (FMR1+), while others lack FMRP (FMR1-). By examining Fmr1- and Fmr1+ cells in Fmr1+/- mosaic female mice we will determine whether the mutant phenotypes that result from deletion of the Fmr1 gene result from cell autonomous or cell non-autonomous processes. This distinction will give important insight into the cellular processes regulated by FMRP and will have implications for treatments for the disease as has been shown for other X-linked dieases (Guy et al., 2007). Furthermore, this is will be the first study to fully characterize the developmental aetiology of mutant phenotypes in female mice lacking FMRP.

We will take advantage of the stereotypical progression of sensory map formation in primary somatosensory cortex to study early developmental processes. Since much work on the roles of FMRP have used hippocampus, we will also focus on the well-characterised CA3 to CA1 connection to examine juvenile neuronal development and plasticity. In both cases all analysis will be conducted at the level of individual neurons. 
Specific Aim 1: To determine whether the Fmr1- and Fmr1+ cells contribute equally to the differentiation of the primary somatosensory cortex in Fmr1+/- female mice. 
Specific Aim 2: To determine whether Fmr1- cells have defects in dendrite and spine development in cortical and hippocampal neurons of Fmr1+/- female mice. 
Specific Aim 3: To determine whether synaptic plasticity in the hippocampus is altered in Fmr1- cells in Fmr1+/- female animals. 

These studies will give valuable insight into the normal function of FMRP in developing neurons and will provide valuable information that will guide future research aimed at finding theapeutic agents to treat FXS.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>635722</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>UMR 5297 (Institute for Interdisciplinary Neuroscience)</gtr:department><gtr:description>Examining the alteration in synaptic structure in FXS</gtr:description><gtr:id>09B23C40-FD4C-4EDF-A6FD-E1D021E3A290</gtr:id><gtr:impact>We have, for the first time, seen alterations in the morphological feature of dendritic spine neck width in FXS.</gtr:impact><gtr:outcomeId>iB4CHiv5MNf-1</gtr:outcomeId><gtr:partnerContribution>They are the experts in this form of microscopy.</gtr:partnerContribution><gtr:piContribution>My Postdoctoral Fellow visited Bordeaux to apply super-resolution microscopy to understand the cellular deficits associated with FXS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Massachusetts Institute of Technology (MIT)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Picower Centre MIT</gtr:department><gtr:description>Understanding the role of FMRP and TSC2 in Cortical Development</gtr:description><gtr:id>A82AF40B-F961-43E7-BF9F-C4293052557E</gtr:id><gtr:impact>As noted above, we hope to have two joint manuscripts , on eon TSC and one on FMRP submitted in the coming months.</gtr:impact><gtr:outcomeId>TDjzzUqDK55-1</gtr:outcomeId><gtr:partnerContribution>Lynsey Meikle spent a year at a laboratory at MIT learning in vivo record of visually-evoked potentials. She is now in the process of setting up this technology in Edinburgh. We also are collaborating with this lab and we expect that the data generated will be included in a manuscript on the role of FMRP in early synaptogenesis to be submitted for publication in the next few months.</gtr:partnerContribution><gtr:piContribution>The TSC project is part of an Lynsey Meikle's Sir Henry Wellcome fellowship. In term of the FXS project, the majority of the research as conducted in our laboratory under this grant. Our collaborators lab is testing whether the smaller than predicted increase in protein synthesis in Fmr1 ko mice results from an increase in protein degradation which will contribute one figure to a nine figure paper which we plan to submit soon.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Seaside Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pharmaceutical Strategies for FXS</gtr:description><gtr:id>A3F4D608-4B28-4C7E-8331-F87B7FD606B1</gtr:id><gtr:impact>The data was published in a high profile paper in Science Translational Medicine.</gtr:impact><gtr:outcomeId>teFESJ9yjeh-1</gtr:outcomeId><gtr:partnerContribution>They also provided data and intellectual input to the project</gtr:partnerContribution><gtr:piContribution>Part of a research team examining the ability of arbaclofen (STX-209) to reverse the cellular alterations in a mouse model of FXS.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Kili4-X thank you event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>7FA82FBB-E184-48DE-8377-B226FFE84636</gtr:id><gtr:impact>It was an evening to say thank you to a group of donors to Fragile X research at the University of Edinburgh. They sponsored a climb of Mount Kilimanjaro.

We are in the process of setting up a Centre for Childhood Cognitive Impairment that focuses on FXS and Autism. These activities are designed to raise its profile.</gtr:impact><gtr:outcomeId>5B73519CB7F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Attended a conference on &quot;Ethics in Autism&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>B9AD8A43-4446-4CE7-9CB8-47F20EDA293D</gtr:id><gtr:impact>Working scientist in the field of autism. Participated in informal discussion concerning therapeutic strategies and the ethical implications in treating autism.

Ongoing process and difficult to assess, but I continue to be invited to these events.</gtr:impact><gtr:outcomeId>LEGYdDGUi9N</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media inteviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>6EDEEA2B-7D6D-4D90-B576-46A4096B69F9</gtr:id><gtr:impact>I have conducted interviews on radio (Five Live) and TV (STV), as well as for numerous newspapers including the Guardian, the Independent and the Times. Some of the interviews resulted from the Neuron paper (Harlow et al., 2010), but most were as a result of the opening of the Patrick Wild Centre, of which I am a Co-director, in November, 2010.

This is difficult to determine, but I hope it as increased the awareness of FXS and other forms of developmental neurological conditions as well as educating the public.</gtr:impact><gtr:outcomeId>CeNSccbkJqT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Facility tour for the board members of Fragile X Society (UK)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>3E9F5705-94E1-4888-8320-E884EE6A9A36</gtr:id><gtr:impact>This has been an ongoing process of interaction between our newly formed Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities.

We are planning on conducting Phase 2b clinical trials with Novartis in the new year. These tours of our laboratories have been instrumental in building a relationship with the Fragile X Society, most of whom are parent of people with FXS.</gtr:impact><gtr:outcomeId>m5Z6haqLQX7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kili4X conference open keynote talks from eminent Neuroscientists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>1416E0CC-CDA8-460A-A8EC-8A075E68122C</gtr:id><gtr:impact>We held an international conference on Fragile X and related learning disabilities in August 2010. At the conference dinner and on the last day of the conference, parents of individuals with FXS and members of the Fragile X SOciety were invited to take part. Several pre-eminent researchers in the field from the University of Edinburgh, Rockefeller University and M.I.T, USA gave open lectures.

The feedback from the parents and the FX Society was very positive, which has strengthened the relationship of the FXS community and the Patrick Wild Centre.</gtr:impact><gtr:outcomeId>TSe1T4a2TFN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Sandoz Lecture</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>56A114A7-483C-464A-8757-6CC5F72376C9</gtr:id><gtr:impact>I presented a poster at a public day.

The aim is to give the public a glimpse into the Psychiatric and Neurological research that takes place at the University of Edinburgh.</gtr:impact><gtr:outcomeId>82FA4DA85B0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Henry Wellcome Postdoctoral Fellowship to Lynsey Meikle</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>74B9154D-A51C-4FB8-8F3D-DEDE73ACA5C1</gtr:id><gtr:outcomeId>44BCCF515550</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>670000000</gtr:amountPounds><gtr:country>India, Republic of</gtr:country><gtr:currCode>INR</gtr:currCode><gtr:currCountryCode>India</gtr:currCountryCode><gtr:currLang>hi_IN</gtr:currLang><gtr:department>Department of Biotechnology, India</gtr:department><gtr:description>Research Centre Grant</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Ministry of Science and Technology India</gtr:fundingOrg><gtr:id>FA4394C7-2ADA-4F2C-8C1C-EB6176F9B1EA</gtr:id><gtr:outcomeId>5460f67ca09d38.49502257</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Autistica Fellowship</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Autistica</gtr:fundingOrg><gtr:id>40B80589-C8E6-401B-A522-82B91C3A45AD</gtr:id><gtr:outcomeId>VjHTxW3gBZq</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1352057</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P006213/1</gtr:fundingRef><gtr:id>3A3417FC-27FD-459C-9366-30CD672D410B</gtr:id><gtr:outcomeId>58c6aef4d167f9.42420360</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Simons Foundation Autism Research Initiative</gtr:department><gtr:description>Simons Initiative for the Developing Brain</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>Simons Foundation</gtr:fundingOrg><gtr:id>F22C9F6E-7DFE-4053-A577-CF6F15533A3C</gtr:id><gtr:outcomeId>58c6ac2a694576.32672839</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>828859</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K014137/1</gtr:fundingRef><gtr:id>592FA4A3-2E94-47D7-AFAD-2531DB0A4F1F</gtr:id><gtr:outcomeId>sMLDU73HJPe</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Shirley Foundation Research Award</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Shirley Foundation</gtr:fundingOrg><gtr:id>F1CC432D-C7AA-4582-ACE1-45DA9A461FCC</gtr:id><gtr:outcomeId>JECTzo9zxNB</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>361A5A30-FFA3-4EB4-9832-0E95F641E197</gtr:id><gtr:title>Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db6d84352d13ccbea74f0c757e4faec"><gtr:id>7db6d84352d13ccbea74f0c757e4faec</gtr:id><gtr:otherNames>Baxter PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_16131_21_21623792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBFDD665-C566-49B1-87BA-5194E44919C2</gtr:id><gtr:title>Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99dd26415861350d64b11d0369403a16"><gtr:id>99dd26415861350d64b11d0369403a16</gtr:id><gtr:otherNames>Till SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5675e9d3ca96e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3868704E-5277-4E00-AD52-8C91047ACB04</gtr:id><gtr:title>Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e10d6af90c85406a9344d36113134714"><gtr:id>e10d6af90c85406a9344d36113134714</gtr:id><gtr:otherNames>Henderson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_16131_21_22993295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BC8CEA8-2B5E-4306-BD2B-C1C1547F1256</gtr:id><gtr:title>The development and activity-dependent expression of aggrecan in the cat visual cortex.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/162614660ebec7fa4e629dc69cc585ba"><gtr:id>162614660ebec7fa4e629dc69cc585ba</gtr:id><gtr:otherNames>Kind PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn><gtr:outcomeId>pm_16131_21_22368089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F63A419E-3FBC-4B01-B756-6EDDD607208C</gtr:id><gtr:title>Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99dd26415861350d64b11d0369403a16"><gtr:id>99dd26415861350d64b11d0369403a16</gtr:id><gtr:otherNames>Till SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16131_21_22328088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75C09B40-1C2A-40E0-A591-B82EC4F70BD6</gtr:id><gtr:title>SynGAP isoforms exert opposing effects on synaptic strength.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0932978ff62bd64864d5ef234f198845"><gtr:id>0932978ff62bd64864d5ef234f198845</gtr:id><gtr:otherNames>McMahon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_16131_21_22692543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3C97A53-A93E-4598-82BE-D494A79504CC</gtr:id><gtr:title>Experience-dependent regulation of functional maps and synaptic protein expression in the cat visual cortex.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc86dac82f8e096b84d410b666142f1e"><gtr:id>dc86dac82f8e096b84d410b666142f1e</gtr:id><gtr:otherNames>Jaffer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pm_16131_21_22512257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>327BB1E2-D227-4887-BBBD-E190858D82AE</gtr:id><gtr:title>Implantation failure in mice with a disruption in Phospholipase C beta 1 gene: lack of embryonic attachment, aberrant steroid hormone signalling and defective endocannabinoid metabolism.</gtr:title><gtr:parentPublicationTitle>Molecular human reproduction</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1069c5c4fc1b4d2f049a55c3dd4c080e"><gtr:id>1069c5c4fc1b4d2f049a55c3dd4c080e</gtr:id><gtr:otherNames>Filis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1360-9947</gtr:issn><gtr:outcomeId>pm_16131_21_23295235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CF9E530-6D9B-476C-BCDE-94C7A6962288</gtr:id><gtr:title>The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21276c6c0852898613c4b12699518537"><gtr:id>21276c6c0852898613c4b12699518537</gtr:id><gtr:otherNames>Martel MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_16131_21_22578505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A7C953E-A23A-4974-83AC-4506B5678C9C</gtr:id><gtr:title>Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c43ca11dee6dacdb11bbe7dcac3609a9"><gtr:id>c43ca11dee6dacdb11bbe7dcac3609a9</gtr:id><gtr:otherNames>Harlow EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>2812B948BF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B2FF8DA-B9A5-49A6-BE2F-6D58EAE74773</gtr:id><gtr:title>Experience-Dependent, Layer-Specific Development of Divergent Thalamocortical Connectivity.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fabb9c192a1ac7ae73f3b1aafe18b57"><gtr:id>4fabb9c192a1ac7ae73f3b1aafe18b57</gtr:id><gtr:otherNames>Crocker-Buque A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn><gtr:outcomeId>5460f51fdf7e38.11754173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74DA895D-80E6-4309-8F47-326884BB528F</gtr:id><gtr:title>Lifting the mood on treating fragile X.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e33c871f6b738a2cc11c8b34499eb5c"><gtr:id>4e33c871f6b738a2cc11c8b34499eb5c</gtr:id><gtr:otherNames>Osterweil EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_16131_21_23121869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E4D90B-145C-4A93-B90A-B76E083B8315</gtr:id><gtr:title>Convergence of Hippocampal Pathophysiology in Syngap+/- and Fmr1-/y Mice.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71645f29d1a3d704b3ad6de6c60a495e"><gtr:id>71645f29d1a3d704b3ad6de6c60a495e</gtr:id><gtr:otherNames>Barnes SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>585d5626025273.94423275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1BB3721-9CD6-4304-B627-159FE55735E0</gtr:id><gtr:title>Fragile X syndrome: from targets to treatments.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/021708c7bd8709f4e4495505def72293"><gtr:id>021708c7bd8709f4e4495505def72293</gtr:id><gtr:otherNames>Wijetunge LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_16131_21_23257237</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700967</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>